EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neurological, Neurodevelopmental and Treatment Outcomes in Patients With Pyruvate Dehydrogenase Complex Deficiency

Antri Savvidou iD, Colin Reilly iD, Kalliopi Sofou iD, Sofia Ygberg iD, Erik A Eklund iD, Karin Naess iD, Niklas Darin iD

Annals of Clinical and Translational Neurology · 06.08.2026

DOI: 10.1002/acn3.70510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 06.08.2026. Verfasst von Antri Savvidou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Göteborgs Frimurares, Swedish State, Linnea and Josef Carlssons Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to characterize intellectual and motor function, neurological features including epilepsy, treatment response, and adaptive behavior in patients with pyruvate dehydrogenase complex deficiency (PDCD) in Sweden.

Methods

Forty‐two individuals with genetically confirmed PDCD (86% PDHA1 ‐related disease) were identified from a nationwide epidemiological study and were included in this cross‐sectional study comprising systematic neurological evaluations ( n = 41) and caregiver interviews assessing adaptive behavior ( n = 35).

Results

Intellectual disability was detected in 33/42 (79%) individuals, while 31/35 (89%) demonstrated significant impairments in adaptive functioning. Although 27/39 (69%) were ambulatory, only 8/39 (21%) demonstrated age‐appropriate walking ability. Clinical signs of polyneuropathy were observed in 24/41 (59%), bulbar symptoms in 22/41 (54%), spasticity in 19/41 (46%), ataxia in 13/41 (32%), and dystonia in 9/41 (22%). Lifetime epilepsy was present in 16/41 (39%) of individuals. Ketogenic diet treatment, administered to 30 individuals, was effective in both prenatal‐ and postnatal‐onset disease. Seizure frequency decreased in individuals with epilepsy (8/9; 89%) and relapses of dystonia, ataxia, exercise intolerance, and lactic acidosis were prevented in all affected individuals (15/15). Improvements in communication and motor function were also noted.

Discussion

Intellectual disability and deficits in adaptive behavior are frequent in PDCD, although cognitive outcomes are more heterogeneous among individuals with postnatal onset. Prenatal onset and epilepsy are associated with severe‐profound intellectual disability. Although most are ambulatory, motor deficits are frequent. A ketogenic diet treatment is a safe and effective therapeutic option, contributing to both seizure control and remission of neurological deterioration relapses.

Schlagwörter

Stichwörter der Autor:innen

adaptive behaviorepilepsyintellectual disabilityketogenic dietpyruvate dehydrogenase

Autor:innen und Institutionen

  • Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Pediatric Neurology and Psychiatry, Sahlgrenska, University Hospital, Gothenburg, Region Västra Götaland, Sweden.
  • Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
  • Neuropediatric Unit, Astrid Lindgren Children's Hospital, Stockholm, Sweden.
  • Section for Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden.

ORCID-Profile: Antri Savvidou, Colin Reilly, Kalliopi Sofou, Sofia Ygberg, Erik A Eklund, Karin Naess, Niklas Darin

Förderung

  • Göteborgs Frimurares
  • Swedish State
  • Linnea and Josef Carlssons Research Foundation
  • H.K.H. Kronprinsessan Lovisas Förening för Barnasjukvård
  • Torbjörn Jebners Foundation

Zitieren

APA

Savvidou, A., Reilly, C., Sofou, K., Ygberg, S., Eklund, E. A., Naess, K., & Darin, N. (2026). Neurological, Neurodevelopmental and Treatment Outcomes in Patients With Pyruvate Dehydrogenase Complex Deficiency. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70510

Vancouver

Savvidou A, Reilly C, Sofou K, Ygberg S, Eklund EA, Naess K, et al. Neurological, Neurodevelopmental and Treatment Outcomes in Patients With Pyruvate Dehydrogenase Complex Deficiency. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70510

BibTeX
@article{Savvidou2026,
  author = {Savvidou, Antri and Reilly, Colin and Sofou, Kalliopi and Ygberg, Sofia and Eklund, Erik A and Naess, Karin and Darin, Niklas},
  title = {Neurological, Neurodevelopmental and Treatment Outcomes in Patients With Pyruvate Dehydrogenase Complex Deficiency},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70510}
}
Kostenlos starten →